Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedApr 26, 2024
DataAggregated Company Financials
Companies34
  • 7D-0.8%
  • 3M-8.9%
  • 1Y55.7%
  • YTD-8.9%

The Pharma is pretty flat in the last 7 days, but Moberg Pharma has stood out, gaining 26%. As for the the longer term, the industry is up 56% over the past 12 months. Earnings are forecast to grow by 49% annually.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Apr 2024kr47.8bkr6.3b-kr1,017,506,529.0776.1x-47x7.6x
Sun, 24 Mar 2024kr51.9bkr6.2b-kr1,038,101,124.2379.6x-50x8.3x
Tue, 20 Feb 2024kr47.0bkr6.1b-kr936,396,161.3584.2x-50.2x7.7x
Thu, 18 Jan 2024kr72.3bkr9.5b-kr1,182,177,292.0071x-61.2x7.6x
Sat, 16 Dec 2023kr66.4bkr9.4b-kr1,184,292,161.0063.3x-56.1x7x
Mon, 13 Nov 2023kr57.6bkr9.5b-kr1,251,439,555.0089.7x-46x6.1x
Wed, 11 Oct 2023kr51.7bkr9.2b-kr1,180,518,247.00117.5x-43.8x5.6x
Fri, 08 Sep 2023kr50.9bkr9.2b-kr1,177,928,977.00138.8x-43.2x5.5x
Sun, 06 Aug 2023kr51.5bkr8.9b-kr1,411,083,410.0086.2x-36.5x5.8x
Tue, 04 Jul 2023kr47.2bkr8.4b-kr1,692,745,033.0072.1x-27.9x5.6x
Thu, 01 Jun 2023kr48.4bkr8.4b-kr1,591,938,619.0078.3x-30.4x5.8x
Sat, 29 Apr 2023kr47.1bkr8.0b-kr1,824,245,158.0096.9x-25.8x5.9x
Mon, 27 Mar 2023kr44.6bkr8.0b-kr1,793,581,316.0083.8x-24.8x5.6x
Wed, 22 Feb 2023kr43.6bkr7.6b-kr2,006,687,458.00215.3x-21.7x5.7x
Fri, 20 Jan 2023kr48.9bkr7.3b-kr1,938,380,981.00291.7x-25.2x6.7x
Sun, 18 Dec 2022kr49.4bkr7.3b-kr1,876,117,427.00276.3x-26.3x6.8x
Tue, 15 Nov 2022kr49.5bkr6.8b-kr1,879,509,895.0056.9x-26.3x7.2x
Thu, 13 Oct 2022kr48.8bkr7.0b-kr1,739,965,048.0046.7x-28.1x7x
Sat, 10 Sep 2022kr52.7bkr7.0b-kr1,737,204,557.0055.4x-30.3x7.6x
Mon, 08 Aug 2022kr52.8bkr6.9b-kr1,535,185,603.0041.3x-34.4x7.7x
Wed, 06 Jul 2022kr52.9bkr5.9b-kr1,509,116,648.0041.4x-35.1x8.9x
Fri, 03 Jun 2022kr53.2bkr5.9b-kr1,514,835,101.0045x-35.1x9x
Sun, 01 May 2022kr54.7bkr5.5b-kr1,339,087,728.0038x-40.9x9.9x
Tue, 29 Mar 2022kr53.0bkr5.4b-kr1,277,657,342.0040.2x-41.5x9.8x
Thu, 24 Feb 2022kr48.7bkr5.3b-kr1,062,074,181.0076.6x-45.9x9.1x
Sat, 22 Jan 2022kr49.1bkr5.5b-kr1,083,939,448.00112.1x-45.3x9x
Mon, 20 Dec 2021kr54.0bkr5.5b-kr1,099,993,442.00109.6x-49.1x9.9x
Wed, 17 Nov 2021kr58.9bkr5.2b-kr1,372,634,926.0087.2x-42.9x11.2x
Fri, 15 Oct 2021kr52.6bkr4.8b-kr1,581,791,452.00136.5x-33.3x11x
Sun, 12 Sep 2021kr58.1bkr4.8b-kr1,560,489,765.26152.6x-37.2x12.1x
Tue, 10 Aug 2021kr54.9bkr4.8b-kr1,412,039,942.26159.8x-38.9x11.5x
Mon, 03 May 2021kr53.9bkr4.6b-kr1,469,283,209.50180.2x-36.7x11.8x
Price to Earnings Ratio

-36.7x


Total Market Cap: kr53.9bTotal Earnings: -kr1,469,283,209.50Total Revenue: kr4.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -37.8x202220232024
Current Industry PE
  • Investors are relatively neutral on the Swedish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 8.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market-0.69%
Healthcare1.97%
Pharma-0.79%
Pharma-0.79%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MOB Moberg Pharmakr34.1425.7%
+kr195.2m
37.1%PB1.6x
CAMX Camuruskr476.600.6%
+kr172.9m
103.7%PE63.7x
CALTX Calliditas Therapeuticskr104.102.1%
+kr112.7m
-15.6%PS4.6x
DICOT Dicotkr0.2513.5%
+kr24.1m
24.9%PB4.6x
CSMED CS Medicakr.6.829.7%
+kr.7.4m
-27.1%PS78.7x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

SECARE

kr54.65

Swedencare

7D

-8.5%

1Y

96.4%

ENZY

kr3.24

Enzymatica

7D

-4.1%

1Y

21.8%

PILA

kr2.15

Pila Pharma

7D

-18.6%

1Y

-24.0%

CALTX

kr104.10

Calliditas Therapeutics

7D

2.1%

1Y

-15.6%

DICOT

kr0.25

Dicot

7D

13.5%

1Y

24.9%

ORX

kr17.00

Orexo

7D

-1.2%

1Y

36.0%

NEWBRY

kr3.32

Newbury Pharmaceuticals

7D

-5.1%

1Y

-39.6%

INDEX

kr0.35

InDex Pharmaceuticals Holding

7D

6.4%

1Y

-9.3%

ONCOZ

kr3.89

OncoZenge

7D

-9.2%

1Y

-53.9%

CSMED

kr.6.82

CS Medica

7D

9.7%

1Y

-27.1%

DANCAN

kr.0.059

Dancann Pharma

7D

133.3%

1Y

-89.3%

IRLAB A

kr11.20

IRLAB Therapeutics

7D

-11.8%

1Y

4.2%

ODI

kr5.70

ODI Pharma

7D

9.6%

1Y

10.7%

MOB

kr34.14

Moberg Pharma

7D

25.7%

1Y

37.1%